Immunogenicity of pembrolizumab in patients with advanced tumors
ConclusionsThe incidence of TE (neutralizing positive) ADAs against pembrolizumab was low in patients with advanced tumors. Furthermore, immunogenicity did not appear to have any clinically relevant effects on the exposure, safety, or efficacy of pembrolizumab.Trial registrationClinicalTrials.gov,NCT01295827 (February 15, 2011),NCT01704287 (October 11, 2012),NCT01866319 (May 31, 2013),NCT01905657 (July 23, 2013),NCT02142738 (May 20, 2014),NCT01848834 (May 8, 2013),NCT02255097 (October 2, 2014),NCT02460198 (June 2, 2015),NCT01953692 (October 1, 2013),NCT02453594 (May 25, 2015),NCT02256436 (October 3, 2014),NCT02335424 (January 9, 2015),NCT02362594 (February 13, 2015).
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
More News: Anaphylactic Shock | Cancer | Cancer & Oncology | Carcinoma | Colorectal Cancer | Head and Neck Cancer | HNSCC | Immunotherapy | Lung Cancer | Lymphoma | Melanoma | Skin Cancer | Squamous Cell Carcinoma | Study